Literature DB >> 12269735

A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid.

Hiroaki Kubota1, Takashi Kanbayashi, Yuzo Tanabe, Jun-ichi Takanashi, Yoichi Kohno.   

Abstract

A 12-year-old girl was diagnosed as having acute disseminated encephalomyelitis and manifested hypersomnia as the main clinical feature. Magnetic resonance imaging (MRI) revealed lesions in the bilateral hypothalamus in addition to other multifocal brain lesions involving the cerebral white matter, brain stem, and basal ganglia. The level of hypocretin in cerebrospinal fluid was decreased in this patient. Corticosteroid treatment resulted in improvement of the hypersomnia and resolution of MRI lesions in the hypothalamus and other regions. This case suggests that the arousal state control mechanism related to the hypocretin peptide/receptor system may be impaired in some patients with acute disseminated encephalomyelitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12269735     DOI: 10.1177/088307380201700713

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  3 in total

1.  Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis.

Authors:  Yasunori Oka; Takashi Kanbayashi; Takahiro Mezaki; Kazumi Iseki; Jun Matsubayashi; Gaku Murakami; Masaru Matsui; Tetsuo Shimizu; Hiroshi Shibasaki
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

2.  [The neurotransmitter, hypocretin. An overview].

Authors:  C Baumann; C Bassetti
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

3.  Daytime somnolence as an early sign of cognitive decline in a community-based study of older people.

Authors:  Angeliki Tsapanou; Yian Gu; Deirdre O'Shea; Teal Eich; Ming-Xin Tang; Nicole Schupf; Jennifer Manly; Molly Zimmerman; Nikolaos Scarmeas; Yaakov Stern
Journal:  Int J Geriatr Psychiatry       Date:  2015-06-15       Impact factor: 3.485

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.